By Dean Seal
Shares of Omega Therapeutics fell after the company disclosed preliminary data from its trial of OTX-2002 in patients with hepatocellular carcinoma and other solid tumors.
The stock was down 25% at $2.24 in premarket trading. When the market closed Monday, shares had fallen 48% year-to-date.
The clinical-stage biotechnology company said Tuesday that the preliminary data was promising.
Eight patients treated with the lead drug candidate demonstrated “clear evidence of on-target epigenetic changes and correlated rapid, robust and durable decreases in MYC mRNA expression levels,” Chief Scientific Officer Thomas McCauley said.
After Omega identifies a recommended dose, the company expects to initiate expansion cohorts in monotherapy and in combination with standard of care therapies.
Write to Dean Seal at [email protected]
Read the full article here
